Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Department of Endocrinology, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.
Medicine (Baltimore). 2022 Jul 1;101(26):e29832. doi: 10.1097/MD.0000000000029832.
Pulmonary hypertension (PHTN) may occur in thyroid disorders, especially in hypothyroidism. However, there is increasing evidence of PHTN in hyperthyroidism (HTH). The etiology, clinical course, management, and factors associated with outcomes of PHTN in the setting of HTH are unascertained. This systematic review consolidates available evidence on patients with HTH who developed PHTN.
We conducted a systematic review on English articles from PubMed, Scopus, and Google Scholar reporting PHTN in patients with hyperthyroidism. Data were analyzed and reported in Microsoft Excel 2020, SPSS version 26, and Jamovi version 1.2.
We identified 589 patients with PHTN in the setting of HTH. Etiologies included Grave disease 66.7%), toxic multinodular goiter (TMNG) (16.8%), drug-induced HTH (0.3%), thyroiditis(0.8%), and toxic adenoma(0.1%). Most patients did not receive any specific management for PHTN and were managed by antithyroid treatment (97.4%). Outcomes of PHTN were reported in 181 patients, with a 94% recovery rate. Pulmonary artery pressures (PAP) before and after HTH management ranged from 22.5 to 75 mm Hg and from 24 to 50 mm Hg, respectively. Outcome analysis performed on data from case reports and series with individually identifiable data revealed a 67.6% female preponderance. An estimated 73.5% of the patients had PHTN at the initial presentation of HTH, which was associated with a better resolution rate of PHTN(OR: 12, P-value: 0.048). TRAB was positive in 47% patients with no clinical difference in outcomes. antiTG AB was reported positive in 29.4%, all of whom had an improvement, compared to an 83.3% improvement rate in those with negative antiTG AB. Various etiologies and treatments did not have any significant differences in the outcome of PHTN.
PHTN can be present at the initial diagnosis of HTH, which is associated with better outcomes of PHTN. There is a clear female preponderance in the development of PHTN. However, resolution rates seem to be better in males. Although TRAB is associated with the development of PHTN, it does not seem to affect the outcomes. PHTN in patients with HTH does not need any specific management, with >90% resolution with antithyroid therapy. Whether any specific antithyroid therapy has a better outcome in PHTN needs to be explored prospectively.
甲状腺疾病,尤其是甲状腺功能减退症,可能会引发肺动脉高压(PHTN)。然而,越来越多的证据表明甲状腺功能亢进症(HTH)也会引发 PHTN。目前尚不清楚 HTH 患者中 PHTN 的病因、临床病程、管理以及与结局相关的因素。本系统评价旨在汇总有关 HTH 患者发生 PHTN 的现有证据。
我们对 PubMed、Scopus 和 Google Scholar 中发表的英文文章进行了系统评价,这些文章报道了甲状腺功能亢进症患者的 PHTN。使用 Microsoft Excel 2020、SPSS 版本 26 和 Jamovi 版本 1.2 对数据进行分析和报告。
我们在 HTH 背景下共确定了 589 例 PHTN 患者。病因包括格雷夫斯病(Grave disease,66.7%)、毒性多结节性甲状腺肿(toxic multinodular goiter,TMNG,16.8%)、药物诱导的 HTH(0.3%)、甲状腺炎(0.8%)和毒性腺瘤(0.1%)。大多数患者未接受任何针对 PHTN 的特定治疗,而是接受抗甲状腺治疗(97.4%)。181 例患者报告了 PHTN 结局,恢复率为 94%。在接受 HTH 治疗前后,肺动脉压(PAP)分别为 22.5 至 75mmHg 和 24 至 50mmHg。对病例报告和系列研究中具有个体可识别数据的分析结果表明,女性占比 67.6%。在 HTH 初始表现时,估计有 73.5%的患者存在 PHTN,这与 PHTN 更好的缓解率相关(OR:12,P 值:0.048)。47%的患者 TRAb 阳性,但结局无临床差异。抗甲状腺球蛋白抗体(antiTG AB)阳性率为 29.4%,所有患者均有改善,而抗 TG AB 阴性患者的改善率为 83.3%。不同病因和治疗方法对 PHTN 的结局均无显著差异。
在 HTH 的初始诊断时可能已经存在 PHTN,这与 PHTN 更好的结局相关。PHTN 的发生明显存在女性优势。然而,男性的缓解率似乎更高。尽管 TRAb 与 PHTN 的发生相关,但似乎不会影响结局。HTH 患者的 PHTN 不需要任何特定的治疗,>90%的患者在接受抗甲状腺治疗后可缓解。是否有任何特定的抗甲状腺治疗对 PHTN 的结局有更好的效果,需要前瞻性研究。